Siemens Healthineers announced today that it completed the acquisition of Advanced Accelerator Applications Molecular Imaging from Novartis. The newly acquired unit is a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans. According to a news release, it will be known as “Advanced Accelerator Applications, a Siemens Healthineers company.” Reports first…

Novavax announced today that it signed a definitive agreement to sell a European manufacturing plant to Novo Nordisk for $200 million. The agreement centers around the company’s facility in Bohumil, Czech Republic, about 25 miles outside of Prague. It includes a transfer of assets, including a 150,000-square-foot, state-of-the-art recombinant protein manufacturing facility. That includes support…

Reckitt Benckiser Group announced today that it is expanding its U.S. manufacturing footprint by acquiring a 310,000 ft² pharmaceutical site in Wilson, North Carolina. The Slough, U.K.–based company said it will invest £155 million ($200 million) to establish a manufacturing facility in Wilson to produce Mucinex tablets and liquids to meet increased U.S. demand. Reckitt…

GE HealthCare (Nasdaq:GEHC) announced today that it will acquire the remaining 50% stake in Nihon Medi-Physics, enabling it to fully own the Japanese radiopharmaceutical company. The purchase from Sumitomo Chemical is expected to close in early 2025, subject to regulatory approvals. Financial terms of the deal were not disclosed. GE HealthCare has already owned a…

GBI Biomanufacturing announced today that it expanded its drug product (DP) services to include automated sterile fill and finish capabilities. Plantation, Florida–based GBI says it can support clients from clinical trials to commercial launch, both for drug products and drug substances. All of this can take place at its Florida plant, delivering advanced and flexible…

Ardena announced today that it received full Good Manufacturing Practice (GMP) approval of its expanded nanomedicine facility in Oss, The Netherlands. The approval enables the pharmaceutical CDMO to conduct GMP manufacturing operations for nanomedicines. It follows a €20 million investment in a state-of-the-art 45,000-square-foot facility offering GMP-compliant Grade C and Grade D cleanrooms designed specifically…

Sekisui Diagnostics announced today that its microbial CDMO business completed construction of a £15.7 million ($20.7 million) drug substance manufacturing capacity expansion. The company completed its cGMP capacity expansion at its U.K. site for clinical-grade drug substance manufacturing. Following appropriate licensure, the expansion can enable manufacturing capabilities for common drug types. Those include enzymes, proteins…

Vitrian announced that it closed a $50 million investment into AmplifyBio and its manufacturing enablement center (AMEC) in Ohio. AmplifyBio, a leading advanced therapy CRO and CDMO, offers a full range of drug development and manufacturing services. The investment, which could scale to $65 million, marks a step toward a larger commitment to support biomanufacturing…

Terumo Blood and Cell Technologies (BCT) announced that it plans to expand its offerings to Latin America. The company plans to help bring automated manufacturing to cell and gene therapy companies in Brazil, Colombia and Mexico. With a focus on automation, it makes products that collect, process and separate blood and cells. The company also…

Samsung Biologics announced a contract manufacturing deal with an unnamed Asia-based pharmaceutical company worth $1.24 billion. According to a news release, it’s the largest contract signed by a single client. Production will take place at Samsung Biologics’ biomanufacturing site in Songdo, South Korea. The contract runs through December 2037. With this agreement, the company’s accumulated…